Barrow, Hanley, Mewhinney & Strauss’s Royalty Pharma RPRX Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Buy	+267,554	New	+$13.9M	0.05%	140

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's RPRX Position: Q2 2026 in Review

Barrow, Hanley, Mewhinney & Strauss opened a new position in Royalty Pharma (RPRX) in Q2 2026: 267,554 shares worth $15M. The stake represents 0.05% of the portfolio and ranks #140 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Barrow, Hanley, Mewhinney & Strauss held 267,554 shares of Royalty Pharma worth $15M as of Q2 2026.
Royalty Pharma was a new Barrow, Hanley, Mewhinney & Strauss position in Q2 2026.
Royalty Pharma made up 0.05% of Barrow, Hanley, Mewhinney & Strauss's portfolio in Q2 2026, its #140 holding.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2026, filed 12 Aug 2026.